Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

ChemoCentryx Completes IPO

RELATED NEWS
Trade NYX now with 
2/13/2012 2:00 PM ET

ChemoCentryx, Inc. (CCXI) said Monday that it has completed its initial public offering of 4.5 million shares of common stock.

In addition, the underwriters of the initial public offering exercised their over-allotment option in full and purchased an additional 675,000 shares of common stock.

All of such shares were sold by ChemoCentryx at an initial public offering price of $10.00 per share.

J.P. Morgan and Citigroup acted as joint book-running managers of the offering, and Cowen and Company acted as co-manager of the offering.

Click here to receive FREE breaking news email alerts for NYSE Euronext and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After failing to sustain an early upward move, stocks have shown a lack of direction over the course of morning trading on Tuesday. The major averages have pulled back near the unchanged line after moving modestly higher in early trading. While a recent series of scandals have caused headaches for the White House, the results of a Washington Post-ABC News poll released Tuesday suggest that the news has not had an impact on President Barack Obama's approval rating. The poll showed that 51 percent of Americans approve of the way Obama is handling his job as president compared to 44 percent that disapprove. U.K. consumer price inflation slowed more-than-expected to a seven-month low in April on falling petrol and air fares, official data revealed Tuesday. The slowdown provides relief for consumers as it raises purchasing power, while it gives more scope for the central bank to ease monetary policy.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.